PreView Medical
PreView Medical is revolutionizing prostate cancer care with its AI-powered Clari Core® systems, which enhance detection and treatment precision. The Clari Core® Biopsy System utilizes real-time spectroscopy to classify prostate tissue as benign or suspicious, significantly improving diagnostic accuracy compared to traditional methods. Additionally, the Clari Core® Mapping System creates a detailed 3D map of cancerous tissues, enabling targeted focal therapy that preserves healthy tissue. With demonstrated high sensitivity and specificity in clinical studies, PreView Medical is positioned to transform prostate cancer management and improve patient outcomes.
PreView Medical
PreView Medical is revolutionizing prostate cancer care with its AI-powered Clari Core® systems, which enhance detection and treatment precision. The Clari Core® Biopsy System utilizes real-time spectroscopy to classify prostate tissue as benign or suspicious, significantly improving diagnostic accuracy compared to traditional methods. Additionally, the Clari Core® Mapping System creates a detailed 3D map of cancerous tissues, enabling targeted focal therapy that preserves healthy tissue. With demonstrated high sensitivity and specificity in clinical studies, PreView Medical is positioned to transform prostate cancer management and improve patient outcomes.
TL;DR
Headquarters: Longmont, Colorado, USA
Founded: 2020
Product focus: AI-powered optical spectroscopy systems for prostate cancer (ClariCore Biopsy & Mapping)
Clinical performance (reported): Sensitivity 86%, Specificity 88%, NPV 97% (144-patient multicenter study)
Funding rounds: Pre-Seed (Feb 24, 2021) and Seed (Jan 1, 2022)
Company Overview
Problem Domain
Prostate cancer detection, localization, and focal therapy guidance
Founded
2020
Industry
Medical devices; Diagnostic imaging
Tech Stack
Funding Track Record
Investor Signal
“SeedFolio; Ulu Ventures”